Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

BACKGROUND: Calcium release-activated calcium (CRAC) channel inhibitors block proinflammatory cytokine release, preserve endothelial integrity and may effectively treat patients with severe COVID-19 pneumonia. METHODS: CARDEA was a phase 2, randomized, double-blind, placebo-controlled trial evaluati...

Full description

Bibliographic Details
Main Authors: Al-Saadi, M. (Author), Bruen, C. (Author), Hebbar, S. (Author), Hou, P.C (Author), Mendoza-Ayala, R. (Author), Michelson, E.A (Author), Miller, J. (Author), Stauderman, K. (Author), Tanios, M. (Author), Zhang, J. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items